表紙
市場調查報告書
商品編碼
1028608

連續/半連續生物加工市場:按製造商類型(創新者/藥物開發商、合同服務提供商)、按公司規模(大、中、小)、按運營規模(臨床前/臨床、商業)

Continuous and Semi-Continuous Bioprocessing Market by Type of Manufacturer (Innovator / Drug Developer and Contract Service Provider), Company Size (Large, Mid-Sized, Small), Scale of Operation (Preclinical / Clinical and Commercial),

出版日期: | 出版商: Roots Analysis | 英文 191 Pages | 商品交期: 最快1-2個工作天內

價格
  • 全貌
  • 簡介
  • 目錄
簡介

多年來,批處理和飼料批處理技術一直是生物製造的唯一可用解決方案。然而,這種方法有一些缺點,例如過程效率低、人為錯誤的風險高、生產速度低等。現代生物製藥需要更快、更高效的技術,並有望無縫過渡到後續流程。換句話說,連續生物工藝方法符合生物製藥所需的無菌製造範式的需求。在此背景下,出現於 1980 年代後期的灌注式生物反應器的推出是該行業的一個里程碑。目前,有多種技術允許連續的下游(澄清/離心、過濾、色譜等)和上游生物過程(細胞系開發、其他預發酵處理等)。一些生物製藥企業,特別是大型製藥企業和大型代工製造服務企業,已經或已經採用了灌註生物反應器、連續層析、連續過濾設備等連續生物工藝技術,有不少公司正在考慮部署。

本報告調查了連續和半連續生物加工市場,並提供了市場概況,以及進入市場的公司的市場狀況、區域趨勢、趨勢和未來前景。

目錄

第 1 章前言

  • 調查範圍
  • 調查方法
  • 重要問題得到解答
  • 章節概述

第 2 章執行摘要

第 3 章介紹

  • 章節概述
  • 連續生物工藝的演變
  • 製藥行業的連續加工
    • 監管狀態
    • 技術的早期採用者
    • 批處理的預期轉變
    • 連續加工的優勢
    • 與連續加工相關的主要問題
    • 未來展望

第 4 章市場情況

  • 章節概述
  • 連續/半連續生物處理:整體市場情況
    • 按成立年份分析
    • 按公司規模分析
    • 按製造商類型分析
    • 按運營規模分析
    • 按公司規模和製造商類型分析
    • 按總部所在地分析
    • 為創新者分析連續和半連續生物處理設施的位置
    • 合同服務提供商連續和半連續生物加工設施的位置分析
    • 按設施類型分析
    • 生物反應器類型分析
    • 生物過程的逐步分析
    • 按生產的生物製藥類型進行分析
    • 產能信息

第 5 章北美的連續生物加工:公司簡介

  • 章節概述
  • AGC Biologics
    • 連續/半連續生物處理功能
    • 近期趨勢和未來前景
  • Biogen
    • 連續/半連續生物處理功能
    • 近期趨勢和未來前景
  • Bristol-Myers Squibb
    • 連續/半連續生物處理功能
    • 近期趨勢和未來前景
  • Sanofi Genzyme
    • 連續/半連續生物處理功能
    • 近期趨勢和未來前景

第 6 章歐洲的連續生物加工:公司簡介

  • 章節概述
  • FUJIFILM Diosynth Biotechnologies
    • 連續/半連續生物處理功能
    • 近期趨勢和未來前景
  • Merck KGaA
    • 連續/半連續生物處理功能
    • 近期趨勢和未來前景
  • Novasep
    • 連續/半連續生物處理功能
    • 近期趨勢和未來前景
  • UCB Pharma
    • 連續/半連續生物處理功能
    • 近期趨勢和未來前景

第 7 章亞太地區的連續生物加工:公司簡介

  • 章節概述
  • Enzene Biosciences
    • 連續/半連續生物處理功能
    • 近期趨勢和未來前景
  • WuXi Biologics
    • 連續/半連續生物處理功能
    • 近期趨勢和未來前景

第 8 章具有持續生物處理能力的內部企業計劃

  • 章節概述
  • 持續關注大公司
    • AbbVie
    • Amgen
    • Bristol-Myers Squibb
    • GlaxoSmithKline
    • Merck
    • Novartis
    • Pfizer
    • Roche
    • Sanofi

第 9 章生物製藥連續製造設備:市場現狀

  • 章節概述
  • 生物製藥連續生產設備:整個市場的市場情況
    • 按設備類型分析
    • 按製造工藝類型分析
    • 生物過程的逐步分析
    • 按運營規模分析
  • 連續生物製藥製造設備供應商
    • 按成立年份分析
    • 按公司規模分析
    • 按總部所在地分析
    • 知名連續製造設備供應商分析

第 10 章成本降低分析

  • 章節概述
  • 涉及連續/半連續生物加工的技術
  • 降低連續/半連續生物加工成本的可能性
    • 上游流程的潛在成本節約
    • 下游工藝的潛在成本節約
  • 重要假設和研究方法
  • 2021-2030 年連續和半連續生物過程總體成本降低的可能性
  • 結論

第 11 章容量分析

  • 章節概述
  • 假設和研究方法
    • 世界的連續和半連續生物處理能力
    • 按公司規模分析
    • 按製造商類型分析
    • 按公司規模和製造商類型分析
    • 按運營規模分析
    • 按總部所在地分析
    • 按地點分析連續和半連續生物處理設施

第 12 章市場預測與機會分析

  • 章節概述
  • 預測性研究方法和關鍵假設
  • 2021-2030 年整體連續/半連續生物加工市場
    • 2021-2030 年連續/準連續生物加工市場:按製造商類型分佈
    • 2021-2030 年連續/準連續生物加工市場:按公司規模分佈
    • 2021-2030 年連續/準連續生物加工市場:按運營規模分佈
    • 2021-2030 年連續/準連續生物加工市場:生物加工的分階段分佈
    • 2021-2030 年連續/準連續生物加工市場:主要地區分佈
  • 2021-2030 年持續的上游生物加工市場
    • 2021-2030 年持續上游生物加工市場:按製造商類型分佈
    • 2021-2030 年持續的上游生物加工市場:按公司規模分佈
    • 2021-2030 年持續上游生物加工市場:按業務規模分佈
    • 2021-2030 年持續的上游生物加工市場:主要地區分佈
  • 2021-2030 年持續的下游生物加工市場
    • 2021-2030 年連續下游生物加工市場:按製造商類型分佈
    • 2021-2030 年持續的下游生物加工市場:按公司規模分佈
    • 2021-2030 年持續的下游生物加工市場:按運營規模分佈
    • 2021-2030 年連續下游生物加工市場:主要地區分佈

第 13 章結論

第 14 章執行洞察力

第 15 章附錄1:匯總數據

第 16 章附錄 2:公司和組織名單

目錄

Title:
Continuous and Semi-Continuous Bioprocessing Market:
by Type of Manufacturer (Innovator / Drug Developer and Contract Service Provider), Company Size (Large, Mid-Sized, Small), Scale of Operation (Preclinical / Clinical and Commercial), Stage of Bioprocess (Upstream and Downstream), Geographical Regions (North America, Europe, Asia Pacific, MENA and Latin America and Rest of the World): Industry Trends and Global Forecasts, 2021-2030.

Overview:

For years, the batch and fed-batch processing technique has been the only available solution for biomanufacturing. However, this method is plagued with several shortcomings, such as process inefficiencies, high risk of human errors and low production speeds. Modern biopharmaceuticals demand faster, and more efficient technologies, preferably with seamless transition into succeeding steps; the primary goal, in this regard, being the preservation of sterility. In other words, a continuous bioprocessing approach is better suited to the needs of the aseptic manufacturing paradigm that is required for biologics. In this context, the introduction of perfusion bioreactors in the late 1980s was a revolutionary development within the industry. Presently, there are multiple available technologies that are capable of supporting continuous downstream (including clarification / centrifugation, filtration, and chromatography steps) and upstream bioprocesses (which include cell line development and other pre-fermentation steps) . A significant number of biopharmaceutical companies, especially certain big pharma players and large contract manufacturing service providers, claim to have already adopted, or are considering installing, continuous bioprocessing technologies, such as perfusion bioreactors, continuous chromatography and continuous filtration equipment. Continuous flow systems have been proven to address a number of challenges associated with traditional bioprocessing; for instance, they facilitate the lowering of manufacturing costs (by 60%), reduction in buffer use (by 30-50%), optimization of resin consumption (by 70%) in chromatography columns, reduction in product change over time (by 90%), improvement of product consistency across different batches (by 50%), minimizing facility footprints (by 50-70%), reduction in operating expenditure (by 90%) and seamless scale up. All the aforementioned advantages eventually serve to improve overall productivity.

The current focus of the users of this novel technology is primarily on upgrading individual operations to the continuous mode; as indicated earlier, some companies have already established bioprocessing lines with multiple continuous processes. Cost, (end product) quality, processing speed and operational flexibility are some of the primary driving factors of the gradual shift to continuous bioprocessing. The COVID-19 pandemic has also contributed to accelerating the adoption of continuous flow systems. Some of the existing challenges in this field include complexities related to defining continuous processes (especially those upstream to the fermentation step) , and aligning the available equipment to operate as per current GMP requirements. Although an end-to-end continuous bioproduction line is still several years away, we believe that the opportunity for both innovators and service providers engaged in this domain is likely to grow in the foreseen future.

Scope of the Report:

The "Continuous and Semi-Continuous Bioprocessing Market by Type of Manufacturer (Innovator / Drug Developer and Contract Service Provider), Company Size (Large, Mid-Sized and Small), Scale of Operation (Preclinical / Clinical and Commercial), Stage of Bioprocess (Upstream and Downstream), Geographical Regions (North America, Europe and Asia Pacific): Industry Trends and Global Forecasts, 2021-2030" report features an extensive study on the companies having continuous and semi-continuous bioprocessing capabilities. The study underlines an in-depth analysis, highlighting the diverse capabilities of stakeholders engaged in this domain. Amongst other elements, the report includes:

  • A detailed review of the overall landscape of the companies that have adopted continuous and semi-continuous bioprocessing, including analyses based on a number of relevant parameters, such as year of establishment, company size, type of manufacturer (innovator / drug developer and contract service provider), scale of operation (preclinical, clinical and commercial), location of headquarters, locations of continuous and semi-continuous bioprocessing facilities of innovators, locations of continuous and semi-continuous bioprocessing facilities of contract service providers, type of facility (modular and conventional), type of bioreactor (single-use and stainless steel), stage of bioprocess (upstream and downstream), primary continuous and semi-continuous bioprocessing (continuous cell culture, continuous clarification / harvesting, continuous purification, process analytical technology and others), secondary continuous and semi-continuous bioprocessing (N-1 stage perfusion, N stage perfusion, continuous concentrated fed-batch, continuous cell retention, continuous centrifugation, continuous chromatography and continuous viral filtration), types of biologics manufactured (antibodies, proteins / peptides, vectors, enzymes and others) and details on the continuous and semi-continuous production capacity.
  • Tabulated profiles of the key players offering a wide range of services for the continuous and semi-continuous bioprocessing of products across North America, Europe and Asia-Pacific. Each profile features a brief overview of the company, financial information (if available), details on its service portfolio, continuous and semi-continuous bioprocessing related capabilities, scale of operation, stage of bioprocess, types of biologics manufactured, continuous and semi-continuous bioprocessing manufacturing facilities, recent developments and an informed future outlook.
  • Key initiatives taken by the leading pharmaceutical companies, taking into consideration both partnered as well as in-house projects.
  • A case study to depict the overall landscape of the continuous and semi-continuous bioprocessing equipment providers, based on a number of parameters, such as type of equipment, type of manufacturing process (continuous and batch-continuous), stage of bioprocess (upstream process and downstream process) and scale of operation (preclinical / clinical and commercial).
  • An insightful analysis highlighting the cost saving potential associated with the adoption of continuous and semi-continuous bioprocessing technologies.
  • A detailed analysis to estimate the global, continuous upstream bioprocessing capacity based on the capacities of various industry stakeholders. The study includes the distribution of capacity, based on company size (small, mid-sized and large), type of manufacturer (innovator / drug developer and contract service provider), scale of operation (preclinical, clinical and commercial), location of headquarters (North America, Europe and Asia-Pacific) and location of continuous and semi-continuous bioprocessing facilities (North America, Europe and Asia-Pacific).

One of the key objectives of the report was to estimate the current market size and the growth opportunities in the continuous and semi-continuous bioprocessing market, over the next decade. Based on different parameters, such as global biopharmaceutical market, cost of goods sold, manufacturing cost of biologics, share of API manufacturing, upstream and downstream costs in biologics manufacturing, we have provided informed estimates on the evolution of the market for the period 2021-2030. In order to provide a detailed future outlook, year-wise projections of the current and forecasted opportunity have been further segmented across [A] type of manufacturer (innovator / drug developer and contract service provider), [B] company size (large, mid-sized and small), [C], scale of operation (preclinical / clinical and commercial), [D] stage of bioprocess (upstream and downstream), and [E] key geographical regions (North America, Europe and Asia-Pacific). In order to account for the uncertainties and to add robustness to our model, we have provided three forecast scenarios, portraying the conservative, base and optimistic tracks of the market's evolution.

The opinions and insights presented in the report are backed by a deep understanding of key insights generated from both secondary and primary research. The perceptions presented in this study were also influenced by discussions held with senior stakeholders in this industry. The report features detailed transcripts of interviews held with the following individuals:

  • Jon Coffman (Senior Director of Bioprocess Technology and Engineering, AstraZeneca)
  • Ehsan Mahdinia (Assistant Professor, Albany College of Pharmacy and Health Sciences)
  • Himanshu Gadgil (Director and Chief Scientific Officer, Enzene Biosciences)

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

Key Questions Answered:

  • Which are the leading contract manufacturers offering expertise in continuous bioprocessing?
  • Which are the leading innovators / drug developers with expertise in continuous bioprocessing?
  • In which regions are majority of the continuous and semi-continuous bioprocessing facilities located?
  • What is the likely cost saving potential of continuous and semi-continuous bioprocessing technology?
  • What is the currently installed global capacity for continuous and semi-continuous bioprocessing?
  • How is the current and future market opportunity likely to be distributed across key market segments?

Chapter Outlines:

Chapter 2 is an executive summary of the insights captured in our research. It offers a high-level view on the likely evolution of the continuous and semi-continuous bioprocessing market in the short to mid-term, and long term.

Chapter 3 provides a general introduction to continuous bioprocessing technology. The chapter describes the historical evolution of continuous bioprocessing in the pharmaceutical industry. It features a brief overview of the regulatory landscape, the early adopters of this technology, opportunities and key challenges associated with the adoption of these techniques. The chapter also discusses the future perspectives of the continuous and semi-continuous bioprocessing market.

Chapter 4 provides an overview of the overall landscape of the companies with capabilities for continuous and semi-continuous bioprocessing, including information on around 60 players engaged in this domain. Additionally, it features an in-depth analysis of the companies, based on a number of parameters, such as year of establishment, company size, type of manufacturer (innovator / drug developer and contract service provider), scale of operation (preclinical, clinical and commercial), location of headquarters, location of continuous and semi-continuous bioprocessing facilities of innovators, location of continuous and semi-continuous bioprocessing facilities of contract service providers, type of facility (modular and conventional), type of bioreactor (single-use and stainless steel), stage of bioprocess (upstream and downstream), primary continuous and semi-continuous bioprocessing (continuous cell culture, continuous clarification / harvesting, continuous purification, process analytical technology and others), secondary continuous and semi-continuous bioprocessing (N-1 stage perfusion, N stage perfusion, continuous concentrated fed-batch, continuous cell retention, continuous centrifugation, continuous chromatography and continuous viral filtration), types of biologics manufactured (antibodies, proteins / peptides, vectors, enzymes and others) and details on the continuous and semi-continuous production capacity.

Chapter 5 includes tabulated profiles of the key stakeholder that have adopted the continuous and semi-continuous bioprocessing technologies and are active in the aforementioned market in North America. Each profile features a brief overview of the company, financial information (if available), details on its service portfolio, continuous and semi-continuous bioprocessing related capabilities, scale of operation, stage of bioprocess, types of biologics manufactured, continuous and semi-continuous bioprocessing manufacturing facilities, recent developments and an informed future outlook.

Chapter 6 includes tabulated profiles of the key stakeholder that have adopted the continuous and semi-continuous bioprocessing technologies and are active in the aforementioned market in Europe. Each profile features a brief overview of the company, financial information (if available), details on its service portfolio, continuous and semi-continuous bioprocessing related capabilities, scale of operation, stage of bioprocess, types of biologics manufactured, continuous and semi-continuous bioprocessing manufacturing facilities, recent developments and an informed future outlook.

Chapter 7 includes tabulated profiles of the key stakeholder that have adopted the continuous and semi-continuous bioprocessing technologies and are active in the aforementioned market in Asia-Pacific. Each profile features a brief overview of the company, financial information (if available), details on its service portfolio, continuous and semi-continuous bioprocessing related capabilities, scale of operation, stage of bioprocess, types of biologics manufactured, continuous and semi-continuous bioprocessing manufacturing facilities, recent developments and an informed future outlook.

Chapter 8 highlights the key initiatives taken by the leading pharmaceutical companies (in terms of revenues generated) , taking into consideration both partnered as well as in-house projects.

Chapter 9 is a case study providing information on more than 80 continuous manufacturing equipment for biologics. It features a detailed analysis based on the type of equipment, type of manufacturing process (continuous and batch-continuous) and stage of bioprocess (upstream process and downstream process) and the scale of operation (preclinical / clinical and commercial). Further, the chapter provides information on equipment provider(s) along with information on their year of establishment, company size, location of headquarters and key players in this domain.

Chapter 10 presents an insightful analysis of the cost saving potential associated with the adoption of continuous and semi-continuous bioprocessing technologies.

Chapter 11 features a detailed analysis of the global, continuous upstream bioprocessing capacity based on the capacities of various industry stakeholders (as available on their respective company websites). The study examines the distribution of capacity, based on the company size (small, mid-sized and large), type of manufacturer (innovator / drug developer and contract service provider), scale of operation (preclinical, clinical and commercial), location of headquarters (North America, Europe and Asia-Pacific) and location of continuous and semi-continuous bioprocessing facilities (North America, Europe and Asia-Pacific).

Chapter 12 presents an insightful market forecast analysis, highlighting the likely growth of the continuous and semi-continuous bioprocessing market till the year 2030. In order to provide an informed future outlook, our projections have been segmented across [A] type of manufacturer (innovator / drug developer and contract service provider), [B] company size (large, mid-sized and small), [C], scale of operation (preclinical / clinical and commercial), [D] stage of bioprocess (upstream and downstream), and [E] key geographical regions (North America, Europe and Asia-Pacific).

Chapter 13 is a summary of the overall report wherein we have mentioned all the key facts and figures described in the chapters. The chapter also highlights the important evolutionary trends that were identified during our research and are expected to influence the continuous and semi-continuous bioprocessing market in the future.

Chapter 14 contains the interview transcripts of the discussions held with key stakeholders engaged in this domain. In this study, we spoke to Jon Coffman (Senior Director of Bioprocess Technology and Engineering, AstraZeneca), Ehsan Mahdinia (Assistant professor, Albany College of Pharmacy and Health Sciences) and Himanshu Gadgil (Director and Chief Scientific Officer, Enzene Biosciences).

Chapter 15 is an appendix, that contains tabulated data and numbers for all the figures provided in the report.

Chapter 16 is an appendix that provides the list of companies and organizations mentioned in the report.

TABLE OF CONTENTS

1. PREFACE

  • 1.1. Scope of the Report
  • 1.2. Research Methodology
  • 1.3. Key Questions Answered
  • 1.4. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION

  • 3.1. Chapter Overview
  • 3.2. Evolution of Continuous Bioprocessing
  • 3.3. Continuous Processing in the Pharmaceutical Industry
    • 3.3.1. Regulatory Landscape
    • 3.3.2. Early Adopters of the Technology
    • 3.3.3. Anticipated Shift from Batch Processing
    • 3.3.4. Advantages of Continuous Processing
    • 3.3.5. Key Challenges Associated with Continuous Processing
    • 3.3.6. Future Perspectives

4. MARKET LANDSCAPE

  • 4.1. Chapter Overview
  • 4.2. Continuous and Semi-Continuous Bioprocessing: Overall Market Landscape
    • 4.2.1. Analysis by Year of Establishment
    • 4.2.2. Analysis by Company Size
    • 4.2.3. Analysis by Type of Manufacturer
    • 4.2.4. Analysis by Scale of Operation
    • 4.2.5. Analysis by Company Size and Type of Manufacturer
    • 4.2.6. Analysis by Location of Headquarters
    • 4.2.7. Analysis of Locations of Continuous and Semi-Continuous Bioprocessing Facilities of Innovators
    • 4.2.8. Analysis of Locations of Continuous and Semi-Continuous Bioprocessing Facilities of Contract Service Providers
    • 4.2.9. Analysis by Type of Facility
    • 4.2.10. Analysis by Type of Bioreactor
    • 4.2.11. Analysis by Stage of Bioprocess
      • 4.2.11.1. Primary Continuous and Semi-Continuous Bioprocessing
      • 4.2.11.2. Secondary Continuous and Semi-Continuous Bioprocessing
    • 4.2.12. Analysis by Types of Biologics Manufactured
    • 4.2.13. Information on Production Capacity

5. CONTINUOUS BIOPROCESSING IN NORTH AMERICA: COMPANY PROFILES

  • 5.1. Chapter Overview
  • 5.2. AGC Biologics
    • 5.2.1. Continuous and Semi-Continuous Bioprocessing Capabilities
    • 5.2.2. Recent Developments and Future Outlook
  • 5.3. Biogen
    • 5.3.1. Continuous and Semi-Continuous Bioprocessing Capabilities
    • 5.3.2. Recent Developments and Future Outlook
  • 5.4. Bristol-Myers Squibb
    • 5.4.1. Continuous and Semi-Continuous Bioprocessing Capabilities
    • 5.4.2. Recent Developments and Future Outlook
  • 5.5. Sanofi Genzyme
    • 5.5.1. Continuous and Semi-Continuous Bioprocessing Capabilities
    • 5.5.2. Recent Developments and Future Outlook

6. CONTINUOUS BIOPROCESSING IN EUROPE: COMPANY PROFILES

  • 6.1. Chapter Overview
  • 6.2. FUJIFILM Diosynth Biotechnologies
    • 6.2.1. Continuous and Semi-Continuous Bioprocessing Capabilities
    • 6.2.2. Recent Developments and Future Outlook
  • 6.3. Merck KGaA
    • 6.3.1. Continuous and Semi-Continuous Bioprocessing Capabilities
    • 6.3.2. Recent Developments and Future Outlook
  • 6.4. Novasep
    • 6.4.1. Continuous and Semi-Continuous Bioprocessing Capabilities
    • 6.4.2. Recent Developments and Future Outlook
  • 6.5. UCB Pharma
    • 6.5.1. Continuous and Semi-Continuous Bioprocessing Capabilities
    • 6.5.2. Recent Developments and Future Outlook

7. CONTINUOUS BIOPROCESSING IN ASIA-PACIFIC: COMPANY PROFILES

  • 7.1. Chapter Overview
  • 7.2. Enzene Biosciences
    • 7.2.1. Continuous and Semi-Continuous Bioprocessing Capabilities
    • 7.2.2. Recent Developments and Future Outlook
  • 7.3. WuXi Biologics
    • 7.3.1. Continuous and Semi-Continuous Bioprocessing Capabilities
    • 7.3.2. Recent Developments and Future Outlook

8. INITIATIVES OF COMPANIES WITH IN-HOUSE CONTINUOUS BIOPROCESSING CAPABILITIES

  • 8.1. Chapter Overview
  • 8.2. Continuous Manufacturing Initiatives of Leading Companies
    • 8.2.1. AbbVie
      • 8.2.1.1. Partnered Initiatives
      • 8.2.1.2. In-House Initiatives
    • 8.2.2. Amgen
      • 8.2.2.1. Partnered Initiatives
      • 8.2.2.2. In-House Initiatives
    • 8.2.3. Bristol-Myers Squibb
      • 8.2.3.1. Partnered Initiatives
      • 8.2.3.2. In-House Initiatives
    • 8.2.4. GlaxoSmithKline
      • 8.2.4.1. Partnered Initiatives
      • 8.2.4.2. In-House Initiatives
    • 8.2.5. Merck
      • 8.2.5.1. Partnered Initiatives
      • 8.2.5.2. In-House Initiatives
    • 8.2.6. Novartis
      • 8.2.6.1. Partnered Initiatives
      • 8.2.6.2. In-House Initiatives
    • 8.2.7. Pfizer
      • 8.2.7.1. Partnered Initiatives
      • 8.2.7.2. In-House Initiatives
    • 8.2.8. Roche
      • 8.2.8.1. Partnered Initiatives
      • 8.2.8.2. In-House Initiatives
    • 8.2.9. Sanofi
      • 8.2.9.1. Partnered Initiatives
      • 8.2.9.2. In-House Initiatives

9. CONTINUOUS MANUFACTURING EQUIPMENT FOR BIOLOGICS: MARKET LANDSCAPE

  • 9.1. Chapter Overview
  • 9.2. Continuous Manufacturing Equipment for Biologic Drugs: Overall Market Landscape
    • 9.2.1. Analysis by Type of Equipment
    • 9.2.2. Analysis by Type of Manufacturing Process
    • 9.2.3. Analysis by Stage of Bioprocess
    • 9.2.4. Analysis by Scale of Operation
  • 9.3. Continuous Manufacturing Equipment Providers for Biologics
    • 9.3.1. Analysis by Year of Establishment
    • 9.3.2. Analysis by Company Size
    • 9.3.3. Analysis by Location of Headquarters
    • 9.3.4. Analysis by Prominent Continuous Manufacturing Equipment Providers

10. COST SAVING ANALYSIS

  • 10.1. Chapter Overview
  • 10.2 Technologies Involved in Continuous and Semi-Continuous Bioprocessing
  • 10.3 Cost Saving Potential of Continuous and Semi-Continuous Bioprocessing
    • 10.3.1. Potential Cost Savings in Upstream Processes
    • 10.3.2. Potential Cost Savings in Downstream Processes
  • 10.4. Key Assumptions and Methodology
  • 10.5 Overall Cost Saving Potential of Continuous and Semi-Continuous Bioprocesses, 2021-2030
  • 10.6 Concluding Remarks

11. CAPACITY ANALYSIS

  • 11.1. Chapter Overview
  • 11.2. Assumptions and Methodology
    • 11.3.1. Global, Continuous and Semi-Continuous Bioprocessing Capacity
    • 11.3.2. Analysis by Company Size
    • 11.3.3. Analysis by Type of Manufacturer
    • 11.3.4. Analysis by Company Size and Type of Manufacturer
    • 11.3.4. Analysis by Scale of Operation
    • 11.3.5. Analysis by Location of Headquarters
    • 11.3.6. Analysis by Location of Continuous and Semi-Continuous Bioprocessing Facilities

12. MARKET FORECAST AND OPPORTUNITY ANALYSIS

  • 12.1. Chapter Overview
  • 12.2. Forecast Methodology and Key Assumptions
  • 12.3. Overall Continuous and Semi-Continuous Bioprocessing Market, 2021-2030
    • 12.3.1. Continuous and Semi-Continuous Bioprocessing Market, 2021-2030: Distribution by Type of Manufacturer
    • 12.3.2. Continuous and Semi-Continuous Bioprocessing Market, 2021-2030: Distribution by Company Size
    • 12.3.3. Continuous and Semi-Continuous Bioprocessing Market, 2021-2030: Distribution by Scale of Operation
    • 12.3.4. Continuous and Semi-Continuous Bioprocessing Market, 2021-2030: Distribution by Stage of Bioprocess
    • 12.3.5. Continuous and Semi-Continuous Bioprocessing Market, 2021-2030: Distribution by Key Geographical Regions
  • 12.4. Continuous Upstream Bioprocessing Market, 2021-2030
    • 12.4.1. Continuous Upstream Bioprocessing Market, 2021-2030: Distribution by Type of Manufacturer
    • 12.4.2. Continuous Upstream Bioprocessing Market, 2021-2030: Distribution by Company Size
    • 12.4.3. Continuous Upstream Bioprocessing Market, 2021-2030: Distribution by Scale of Operation
    • 12.4.4. Continuous Upstream Bioprocessing Market, 2021-2030: Distribution by Key Geographical Regions
  • 12.5. Continuous Downstream Bioprocessing Market, 2021-2030
    • 12.5.1. Continuous Downstream Bioprocessing Market, 2021-2030: Distribution by Type of Manufacturer
    • 12.5.2. Continuous Downstream Bioprocessing Market, 2021-2030: Distribution by Company Size
    • 12.5.3. Continuous Downstream Bioprocessing Market, 2021-2030: Distribution by Scale of Operation
    • 12.5.4. Continuous Downstream Bioprocessing Market, 2021-2030: Distribution by Key Geographical Regions

13. CONCLUSION

14. EXECUTIVE INSIGHTS

  • 14.1. Chapter Overview
  • 14.2. AstraZeneca
    • 14.2.1. Overview of Company / Organization
    • 14.2.2. Interview Transcript: Jon Coffman, Senior Director of Bioprocess Technology and Engineering
  • 14.3. Enzene Biosciences
    • 14.3.1. Overview of Company / Organization
    • 14.3.2. Interview Transcript: Himanshu Gadgil, Director and Chief Scientific Officer
  • 14.4. Albany College of Pharmacy and Health Sciences
    • 14.4.1. Overview of Company / Organization
    • 14.4.2. Interview Transcript: Ehsan Mahdinia, Assistant Professor

15. APPENDIX 1: TABULATED DATA

16. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

List Of Figures

  • Figure 3.1 Advantages of Continuous Bioprocessing
  • Figure 4.1 Continuous and Semi-Continuous Bioprocessing: Distribution by Year of Establishment
  • Figure 4.2 Continuous and Semi-Continuous Bioprocessing: Distribution by Company Size
  • Figure 4.3 Continuous and Semi-Continuous Bioprocessing: Distribution by Type of Manufacturer
  • Figure 4.4 Continuous and Semi-Continuous Bioprocessing: Distribution by Scale of Operation
  • Figure 4.5 Continuous and Semi-Continuous Bioprocessing: Distribution by Company Size and Type of Manufacturer
  • Figure 4.6 Continuous and Semi-Continuous Bioprocessing: Distribution by Location of Headquarters
  • Figure 4.7 Continuous and Semi-Continuous Bioprocessing: Distribution by Location of Facilities of Innovators
  • Figure 4.8 Continuous and Semi-Continuous Bioprocessing: Distribution by Locations of Facilities of Contract Service Providers
  • Figure 4.9 Continuous and Semi-Continuous Bioprocessing: Distribution by Type of Facility
  • Figure 4.10 Continuous and Semi-Continuous Bioprocessing: Distribution by Type of Bioreactor
  • Figure 4.11 Continuous and Semi-Continuous Bioprocessing: Distribution by Type of Facility and Type of Bioreactor
  • Figure 4.12 Continuous and Semi-Continuous Bioprocessing: Distribution by Stage of Bioprocess
  • Figure 4.13 Continuous and Semi-Continuous Bioprocessing: Distribution by Primary Continuous and Semi-Continuous Bioprocessing
  • Figure 4.14 Continuous and Semi-Continuous Bioprocessing: Distribution by Secondary Continuous and Semi-Continuous Bioprocessing
  • Figure 4.15 Continuous and Semi-Continuous Bioprocessing: Distribution by Type of Biologic Manufactured
  • Figure 8.1 Continuous Manufacturing Initiatives: AbbVie
  • Figure 8.2 Continuous Manufacturing Initiatives: Amgen
  • Figure 8.3 Continuous Manufacturing Initiatives: Bristol-Myers Squibb
  • Figure 8.4 Continuous Manufacturing Initiatives: GlaxoSmithKline
  • Figure 8.5 Continuous Manufacturing Initiatives: Merck
  • Figure 8.6 Continuous Manufacturing Initiatives: Novartis
  • Figure 8.7 Continuous Manufacturing Initiatives: Pfizer
  • Figure 8.8 Continuous Manufacturing Initiatives: Roche
  • Figure 8.9 Continuous Manufacturing Initiatives: Sanofi
  • Figure 9.1 Continuous Manufacturing Equipment for Biologic Drugs: Distribution by Type of Equipment
  • Figure 9.2 Continuous Manufacturing Equipment for Biologic Drugs: Distribution by Type of Manufacturing Process
  • Figure 9.3 Continuous Manufacturing Equipment for Biologic Drugs: Distribution by Stage of Bioprocess
  • Figure 9.4 Continuous Manufacturing Equipment for Biologic Drugs: Distribution by Scale of Operation
  • Figure 9.5 Continuous Manufacturing Equipment Providers for Biologic Drugs: Distribution by Year of Establishment
  • Figure 9.6 Continuous Manufacturing Equipment Providers for Biologic Drugs: Distribution by Company Size
  • Figure 9.7 Continuous Manufacturing Equipment Providers for Biologic Drugs: Distribution by Location of Headquarters
  • Figure 9.8 Key Players: Distribution by Continuous Manufacturing Equipment for Biologic Drugs
  • Figure 10.1 Technologies Involved: Hybrid vs Fully Integrated Continuous Technologies
  • Figure 10.2 Overall Cost Saving Potential of Continuous and Semi-Continuous Bioprocess Techniques, 2021-2030 (USD Billion)
  • Figure 11.1 Global, Continuous and Semi-Continuous Upstream Bioprocessing Capacity: Distribution by Company Size (Range of Capacity)
  • Figure 11.2 Global, Continuous and Semi-Continuous Upstream Bioprocessing Capacity: Distribution by Company Size (in Kg/Year)
  • Figure 11.3 Global, Continuous and Semi-Continuous Upstream Bioprocessing Capacity: Distribution by Type of Manufacturer (in Kg/Year)
  • Figure 11.4 Global, Continuous and Semi-Continuous Upstream Bioprocessing Capacity: Distribution by Company Size and Type of Manufacturer (in Kg/Year)
  • Figure 11.5 Global, Continuous and Semi-Continuous Upstream Bioprocessing Capacity: Distribution by Scale of Operation (in Kg/Year)
  • Figure 11.6 Global, Continuous and Semi-Continuous Upstream Bioprocessing Capacity: Distribution by Location of Headquarters (in Kg/Year)
  • Figure 11.7 Global, Continuous and Semi-Continuous Upstream Bioprocessing Capacity: Distribution by Location of Continuous and Semi-Continuous Bioprocessing Facilities (in Kg/Year)
  • Figure 12.1 Overall Continuous and Semi-Continuous Bioprocessing Market, 2021-2030 (USD Million)
  • Figure 12.2 Continuous and Semi-Continuous Bioprocessing Market, 2021-2030: Distribution by Type of Manufacturer (USD Million)
  • Figure 12.3 Continuous and Semi-Continuous Bioprocessing Market, 2021-2030: Distribution by Company Size (USD Million)
  • Figure 12.4 Continuous and Semi-Continuous Bioprocessing Market, 2021-2030: Distribution by Scale of Operation (USD Million)
  • Figure 12.5 Continuous and Semi-Continuous Bioprocessing Market, 2021-2030: Distribution by Stage of Bioprocess (USD Million)
  • Figure 12.6 Continuous and Semi-Continuous Bioprocessing Market, 2021-2030: Distribution by Market in Key Geographical Regions (USD Million)
  • Figure 12.7 Continuous Upstream Bioprocessing Market, 2021-2030 (USD Million)
  • Figure 12.8 Continuous Upstream Bioprocessing Market, 2021-2030: Distribution by Type of Manufacturer (USD Million)
  • Figure 12.9 Continuous Upstream Bioprocessing Market, 2021-2030: Distribution by Company Size (USD Million)
  • Figure 12.10 Continuous Upstream Bioprocessing Market, 2021-2030: Distribution by Scale of Operation (USD Million)
  • Figure 12.11 Continuous Upstream Bioprocessing Market, 2021-2030: Distribution by Market in Key Geographical Regions (USD Million)
  • Figure 12.12 Continuous Downstream Bioprocessing Market, 2021-2030 (USD Million)
  • Figure 12.13 Continuous Downstream Bioprocessing Market, 2021-2030: Distribution by Type of Manufacturer (USD Million)
  • Figure 12.14 Continuous Downstream Bioprocessing Market, 2021-2030: Distribution by Company Size (USD Million)
  • Figure 12.15 Continuous Downstream Bioprocessing Market, 2021-2030: Distribution by Scale of Operation (USD Million)
  • Figure 12.16 Continuous Downstream Bioprocessing Market, 2021-2030: Distribution by Market in Key Geographical Regions (USD Million)
  • Figure 13.1 Concluding Remarks: Market Landscape
  • Figure 13.2 Concluding Remarks: Capacity Analysis
  • Figure 13.3 Concluding Remarks: Recent Expansions
  • Figure 13.4 Concluding Remarks: Cost Saving Analysis
  • Figure 13.5 Concluding Remarks: Market Sizing and Opportunity Analysis for Continuous and Semi-Continuous Bioprocessing Market

List Of Tables

  • Table 3.1 Early Adopters of Continuous Bioprocess Technology
  • Table 3.2 Batch Processing Technique versus Continuous Processing Technique: Comparison of Characteristics
  • Table 4.1 List of Companies with Expertise in Continuous and Semi-Continuous Bioprocessing
  • Table 4.2 Continuous and Semi-Continuous Bioprocessing Facilities: Information on Scale of Operation
  • Table 4.3 Continuous and Semi-Continuous Bioprocessing Facilities: Information on Type of Facility and Type of Bioreactor
  • Table 4.4 Continuous and Semi-Continuous Bioprocessing Facilities: Information on Stage of Bioprocess
  • Table 4.5 Continuous and Semi-Continuous Bioprocessing Facilities: Information on Primary Continuous and Semi-Continuous Bioprocessing
  • Table 4.6 Continuous and Semi-Continuous Bioprocessing Facilities: Information on Secondary Continuous and Semi-Continuous Bioprocessing
  • Table 4.7 Continuous and Semi-Continuous Bioprocessing Facilities: Information on Types of Biologics Manufactured
  • Table 4.8 Continuous and Semi-Continuous Bioprocessing Facilities: Information on Production Capacity
  • Table 5.1 AGC Biologics: Company Snapshot
  • Table 5.2 AGC Biologics: Continuous and Semi-Continuous Bioprocessing Capabilities
  • Table 5.3 AGC Biologics: Recent Developments and Future Outlook
  • Table 5.4 Biogen: Company Snapshot
  • Table 5.5 Biogen: Continuous and Semi-Continuous Bioprocessing Capabilities
  • Table 5.6 Biogen: Recent Developments and Future Outlook
  • Table 5.7 Bristol-Myers Squibb: Company Snapshot
  • Table 5.8 Bristol-Myers Squibb: Continuous and Semi-Continuous Bioprocessing Capabilities
  • Table 5.9 Bristol-Myers Squibb: Recent Developments and Future Outlook
  • Table 5.10 Sanofi Genzyme: Company Snapshot
  • Table 5.11 Sanofi Genzyme: Continuous and Semi-Continuous Bioprocessing Capabilities
  • Table 5.12 Sanofi Genzyme: Recent Developments and Future Outlook
  • Table 6.1 FUJIFILM Diosynth Biotechnologies: Company Snapshot
  • Table 6.2 FUJIFILM Diosynth Biotechnologies: Continuous and Semi-Continuous Bioprocessing Capabilities
  • Table 6.3 FUJIFILM Diosynth Biotechnologies: Recent Developments and Future Outlook
  • Table 6.4 Merck KGaA: Company Snapshot
  • Table 6.5 Merck KGaA: Continuous and Semi-Continuous Bioprocessing Capabilities
  • Table 6.6 Merck KGaA: Recent Developments and Future Outlook
  • Table 6.7 Novasep: Company Snapshot
  • Table 6.8 Novasep: Continuous and Semi-Continuous Bioprocessing Capabilities
  • Table 6.9 Novasep: Recent Developments and Future Outlook
  • Table 6.10 UCB Pharma: Company Snapshot
  • Table 6.11 UCB Pharma: Continuous and Semi-Continuous Bioprocessing Capabilities
  • Table 6.12 UCB Pharma: Recent Developments and Future Outlook
  • Table 7.1 Enzene Biosciences: Company Snapshot
  • Table 7.2 Enzene Biosciences: Continuous and Semi-Continuous Bioprocessing Capabilities
  • Table 7.3 Enzene Biosciences: Recent Developments and Future Outlook
  • Table 7.4 WuXi Biologics: Company Snapshot
  • Table 7.5 WuXi Biologics: Continuous and Semi-Continuous Bioprocessing Capabilities
  • Table 7.6 WuXi Biologics: Recent Developments and Future Outlook
  • Table 8.1 AbbVie: Partnered Initiatives
  • Table 8.2 AbbVie: In-House Initiatives
  • Table 8.3 Amgen: Partnered Initiatives
  • Table 8.4 Amgen: In-House Initiatives
  • Table 8.5 Bristol-Myers Squibb: Partnered Initiatives
  • Table 8.6 Bristol-Myers Squibb: In-House Initiatives
  • Table 8.7 GlaxoSmithKline: Partnered Initiatives
  • Table 8.8 GlaxoSmithKline: In-House Initiatives
  • Table 8.9 Merck: Partnered Initiatives
  • Table 8.10 Merck: In-House Initiatives
  • Table 8.11 Novartis: Partnered Initiatives
  • Table 8.12 Novartis: In-House Initiatives
  • Table 8.13 Pfizer: Partnered Initiatives
  • Table 8.14 Pfizer: In-House Initiatives
  • Table 8.15 Roche: Partnered Initiatives
  • Table 8.16 Roche: In-House Initiatives
  • Table 8.17 Sanofi: Partnered Initiatives
  • Table 8.18 Sanofi: In-House Initiatives
  • Table 9.1 Continuous Manufacturing Equipment for Biologics: Information on Type of Equipment, Type of Manufacturing Process and Stage of Bioprocess
  • Table 9.2 Continuous Manufacturing Equipment for Biologics: Information on Scale of Operation and Throughput / Capacity
  • Table 9.3 Continuous Manufacturing Equipment Providers for Biologics: Information of Year of Establishment, Company Size and Location of Headquarters
  • Table 10.1 Continuous and Semi-Continuous Bioprocessing: Cost Saving Potential Associated with Continuous Upstream Process
  • Table 10.2 Continuous and Semi-Continuous Bioprocessing: Cost Saving Potential of AcuSyst Perfusion Bioreactors
  • Table 10.3 Continuous and Semi-Continuous Bioprocessing: Cost Saving Potential Associated with Continuous Downstream Process
  • Table 11.1 Global Continuous and Semi-Continuous Bioprocessing Capacity: Average Upstream Capacity by Company Size (Sample Data Set)
  • Table 14.1 AstraZeneca: Company / Organization Snapshot
  • Table 14.2 Enzene Biosciences: Company / Organization Snapshot
  • Table 14.3 Albany College of Pharmacy and Health Sciences: Company / Organization Snapshot
  • Table 15.1 Continuous and Semi-Continuous Bioprocessing: Distribution by Year of Establishment
  • Table 15.2 Continuous and Semi-Continuous Bioprocessing: Distribution by Company Size
  • Table 15.3 Continuous and Semi-Continuous Bioprocessing: Distribution by Type of Manufacturer
  • Table 15.4 Continuous and Semi-Continuous Bioprocessing: Distribution by Scale of Operation
  • Table 15.5 Continuous and Semi-Continuous Bioprocessing: Distribution by Company Size and Type of Manufacturer
  • Table 15.6 Continuous and Semi-Continuous Bioprocessing: Distribution by Location of Headquarters
  • Table 15.7 Continuous and Semi-Continuous Bioprocessing: Distribution by Locations of Facilities of Innovators
  • Table 15.8 Continuous and Semi-Continuous Bioprocessing: Distribution by Locations of Facilities of Contract Service Providers
  • Table 15.9 Continuous and Semi-Continuous Bioprocessing: Distribution by Type of Facility
  • Table 15.10 Continuous and Semi-Continuous Bioprocessing: Distribution by Type of Bioreactor
  • Table 15.11 Continuous and Semi-Continuous Bioprocessing: Distribution by Type of Facility and Type of Bioreactor
  • Table 15.12 Continuous and Semi-Continuous Bioprocessing: Distribution by Stage of Bioprocess
  • Table 15.13 Continuous and Semi-Continuous Bioprocessing: Distribution by Primary Continuous and Semi-Continuous Bioprocessing
  • Table 15.14 Continuous and Semi-Continuous Bioprocessing: Distribution by Secondary Continuous and Semi-Continuous Bioprocessing
  • Table 15.15 Continuous and Semi-Continuous Bioprocessing: Distribution by Type of Biologic Manufactured
  • Table 15. 16 Continuous Manufacturing Equipment for Biologic Drugs: Distribution by Type of Equipment
  • Table 15.17 Continuous Manufacturing Equipment for Biologic Drugs: Distribution by Type of Manufacturing Process
  • Table 15.18 Continuous Manufacturing Equipment for Biologic Drugs: Distribution by Stage of Bioprocess
  • Table 15.19 Continuous Manufacturing Equipment for Biologic Drugs: Distribution by Scale of Operation
  • Table 15.20 Continuous Manufacturing Equipment Providers for Biologic Drugs: Distribution by Year of Establishment
  • Table 15.21 Continuous Manufacturing Equipment Providers for Biologic Drugs: Distribution by Company Size
  • Table 15.22 Continuous Manufacturing Equipment Providers for Biologic Drugs: Distribution by Location of Headquarters
  • Table 15.23 Key Players: Distribution by Continuous Manufacturing Equipment for Biologic Drugs
  • Table 15.24 Technologies Involved: Hybrid vs Fully Integrated Continuous Technologies
  • Table 15.25 Overall Cost Saving Potential of Continuous and Semi-Continuous Bioprocessing Techniques, 2021-2030 (USD Billion)
  • Table 15.26 Global, Continuous and Semi-Continuous Upstream Bioprocessing Capacity: Distribution by Company Size (Range of Capacity)
  • Table 15.27 Global, Continuous and Semi-Continuous Upstream Bioprocessing Capacity: Distribution by Company Size (in Kg/Year)
  • Table 15.28 Global, Continuous and Semi-Continuous Upstream Bioprocessing Capacity: Distribution by Type of Manufacturer (in Kg/Year)
  • Table 15.29 Global, Continuous and Semi-Continuous Upstream Bioprocessing Capacity: Distribution by Company Size and Type of Manufacturer (in Kg/Year)
  • Table 15.30 Global, Continuous and Semi-Continuous Upstream Bioprocessing Capacity: Distribution by Scale of Operation (in Kg/Year)
  • Table 15.31 Global, Continuous and Semi-Continuous Upstream Bioprocessing Capacity: Distribution by Location of Headquarters (in Kg/Year)
  • Table 15.32 Global, Continuous and Semi-Continuous Upstream Bioprocessing Capacity: Distribution by Location of Continuous and Semi-Continuous Bioprocessing Facilities (in Kg/Year)
  • Table 15.33 Overall Continuous and Semi-Continuous Bioprocessing Market, Conservative, Base and Optimistic Scenarios, 2021-2030
  • Table 15.34 Continuous and Semi-Continuous Bioprocessing Market, Conservative, Base and Optimistic Scenarios, 2021-2030: Distribution by Type of Manufacturer (USD Million)
  • Table 15.35 Continuous and Semi-Continuous Bioprocessing Market, Conservative, Base and Optimistic Scenarios, 2021-2030: Distribution by Company Size (USD Million)
  • Table 15.36 Continuous and Semi-Continuous Bioprocessing Market, Conservative, Base and Optimistic Scenarios, 2021-2030: Distribution by Scale of Operation (USD Million)
  • Table 15.37 Continuous and Semi-Continuous Bioprocessing Market, Conservative, Base and Optimistic Scenarios, 2021-2030: Distribution by Stage of Bioprocess (USD Million)
  • Table 15.38 Continuous and Semi-Continuous Bioprocessing Market, Conservative, Base and Optimistic Scenarios, 2021-2030: Distribution by Market in Key Geographical Regions (USD Million)
  • Table 15.39 Continuous Upstream Bioprocessing Market, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
  • Table 15.40 Continuous Upstream Bioprocessing Market, Conservative, Base and Optimistic Scenarios, 2021-2030: Distribution by Type of Manufacturer (USD Million)
  • Table 15.41 Continuous Upstream Bioprocessing Market, Conservative, Base and Optimistic Scenarios, 2021-2030: Distribution by Company Size (USD Million)
  • Table 15.42 Continuous Upstream Bioprocessing Market, Conservative, Base and Optimistic Scenarios, 2021-2030: Distribution by Scale of Operation (USD Million)
  • Table 15.43 Continuous Upstream Bioprocessing Market, Conservative, Base and Optimistic Scenarios, 2021-2030: Distribution by Market in Key Geographical Regions (USD Million)
  • Table 15.44 Continuous Downstream Bioprocessing Market, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
  • Table 15.45 Continuous Downstream Bioprocessing Market, Conservative, Base and Optimistic Scenarios, 2021-2030: Distribution by Type of Manufacturer (USD Million)
  • Table 15.46 Continuous Downstream Bioprocessing Market, Conservative, Base and Optimistic Scenarios, 2021-2030: Distribution by Company Size (USD Million)
  • Table 15.47 Continuous Downstream Bioprocessing Market, Conservative, Base and Optimistic Scenarios, 2021-2030: Distribution by Scale of Operation (USD Million)
  • Table 15.48 Continuous Downstream Bioprocessing Market, Conservative, Base and Optimistic Scenarios, 2021-2030: Distribution by Market in Key Geographical Regions (USD Million)

List Of Companies

  • 1. 3D Biotek
  • 2. 3P Biopharmaceuticals
  • 3. AbbVie
  • 4. ABL Europe
  • 5. Abzena
  • 6. Accenture
  • 7. AGC Biologics
  • 8. AIM ImmunoTech
  • 9. Alexanderwerk
  • 10. Alvotech
  • 11. Amgen
  • 12. AmpTec
  • 13. Applikon Biotechnology
  • 14. Aprogen
  • 15. AstraZeneca
  • 16. Avid Bioservices (formerly Peregrine Pharmaceuticals)
  • 17. Baxter
  • 18. Bayer
  • 19. bbi-biotech
  • 20. BIBITEC
  • 21. BINEX
  • 22. Biogen
  • 23. BioMarin Pharmaceutical
  • 24. Bionova Scientific
  • 25. BiosanaPharma
  • 26. Bio-Thera Solutions
  • 27. Biovian
  • 28. bluebird bio
  • 29. Boehringer Ingelheim BioXcellence
  • 30. Bonumose
  • 31. Bristol-Myers Squibb
  • 32. Changchun High & New Technology
  • 33. Canton Biologics
  • 34. CCHT Biopharmaceutical
  • 35. Celgene
  • 36. Cell and Gene Therapy Catapult
  • 37. Cell Culture Company
  • 38. CELLEC Biotek
  • 39. Celonic
  • 40. Centre for Process Innovation (CPI)
  • 41. Cerbios-Pharma
  • 42. CMAC
  • 43. Cobra Biologics
  • 44. Codiak BioSciences
  • 45. Coperion
  • 46. Creative Biolabs
  • 47. CSL Behring
  • 48. Cytiva
  • 49. Cytovance Biologics
  • 50. DCI-Biolafitte
  • 51. DEVEX Verfahrenstechnik
  • 52. DSM Pharmaceutical
  • 53. Durham University
  • 54. Eli Lilly
  • 55. Engage Therapeutics (Acquired by UCB Pharma)
  • 56. Enzene Biosciences
  • 57. Eppendorf
  • 58. Esco Aster
  • 59. ETH Zurich
  • 60. EV Biologics
  • 61. Evotec
  • 62. Exelixis
  • 63. Exothera
  • 64. Forbius
  • 65. FUJIFILM Diosynth Biotechnologies
  • 66. Gallus BioPharmaceuticals (Acquired by Patheon)
  • 67. G-CON Manufacturing
  • 68. GEA
  • 69. Genzyme
  • 70. Global BioTherapeutics (GBT)
  • 71. Glycotope
  • 72. Goodwin Biotechnology
  • 73. GTP Technology
  • 74. HAL Allergy
  • 75. HALIX
  • 76. Handl Therapeutics
  • 77. Hemispherx Biopharma
  • 78. HJB
  • 79. Horizon Therapeutics
  • 80. Janssen Pharmaceuticals
  • 81. Johnson & Johnson
  • 82. Just-Evotec Biologics
  • 83. KBI Biopharma
  • 84. Kemwell Biopharma
  • 85. Kiadisto
  • 86. Kymab
  • 87. Lonza
  • 88. Luina Bio
  • 89. Lupin
  • 90. MabSpace Biosciences
  • 91. Medix Biochemica
  • 92. Merck
  • 93. Merck KGaA
  • 94. Microsoft
  • 95. MolMed
  • 96. Mycenax Biotech
  • 97. MyoKardia (acquired by Bristol-Myers Squibb)
  • 98. National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL)
  • 99. National Resilience
  • 100. Natrix Separations (Acquired by Merck)
  • 101. Nightstar Therapeutics (acquired by Biogen)
  • 102. Novartis
  • 103. Novasep
  • 104. Novavax
  • 105. Novo Nordisk
  • 106. Ology Bioservices
  • 107. OmniBRx Biotechnologies
  • 108. OXGENE (Acquired by WuXi AppTec)
  • 109. PacificGMP
  • 110. Pall Biotech
  • 111. Pall Life Sciences
  • 112. Pfizer
  • 113. Pierre Fabre
  • 114. PIERRE GUERIN
  • 115. Polymun Scientific
  • 116. ProBioGen
  • 117. Rentschler Biopharma
  • 118. Repligen
  • 119. Sage Therapeutics
  • 120. Samsung Biologics
  • 121. Sangamo Therapeutics
  • 122. Sanofi Genzyme
  • 123. Sartorius
  • 124. Semba Biosciences
  • 125. Servier
  • 126. Shire
  • 127. Sturtevant
  • 128. Syngene
  • 129. Synthecon
  • 130. TA Instruments
  • 131. ThalesNano
  • 132. The Rockefeller University
  • 133. Thermo Fisher Scientific
  • 134. Tidal Therapeutics (Acquired by Sanofi)
  • 135. Transcenta
  • 136. Translate Bio
  • 137. UCB Pharma
  • 138. UIC College of Pharmacy
  • 139. Universitas Indonesia
  • 140. University of Strathclyde
  • 141. Vapourtec
  • 142. Vigene Biosciences
  • 143. WuXi Biologics
  • 144. WuXi STA
  • 145. XPure
  • 146. YMC Process Technologies